The aim of the study was to evaluate the effect of endothelin-1 receptor antagonists (ETRAs) on skin fibrosis in systemic sclerosis (SSc) patients from the (EULAR Scleroderma Trials and Research) EUSTAR cohort.
Methods
SSc patients from the EUSTAR cohort with at least three visits (pre-study visit without ETRA treatment, baseline and follow-up visit with ETRA treatment) were included. The control group consisted of SSc patients with the same inclusion criteria, but without ETRA treatment. The primary endpoint was the comparison of the delta change of the modified Rodnan skin score (mRSS) between baseline and follow-up in the ETRA versus the control group.
Results
Data on 75 ETRA treated (68 bosentan, 1 sitaxentan, 6 ambrisentan) and 969 control patients were included. The delta change of mRSS was not significantly different between the ETRA group and the control group (n = 969; 0 (-2-1) vs. n = 75; 0 (-2-1); p = 0.4). Similarly, subgroup analysis on patients with diffuse, extended SSc disease (mRSS ≥16) did not show differences in the delta change of mRSS between the ETRA group and the control group (n = 125; −1 [-7-0] vs. n = 23; −1 [-7-2], p = 0.8). Likewise, diffuse SSc patients with mRSS 7-21 at baseline, reflecting recently identified enrichment criteria for clinical trials, did not show any difference between the ETRA and the control group (n = 219; −1 [-3-1] vs. n = 27; −1 [-3-2]; p = 0.5).
Conclusions
This controlled, observational, real-life cohort study with a large sample size did not show effects of ETRAs on skin fibrosis in patients with SSc.
SoldanoSMontagnaPVillaggioBet al.Endothelin and sex hormones modulate the fibronectin synthesis by cultured human skin scleroderma fibroblasts.Ann Rheum Dis2009;68:(4)599-602
2.
KuhnAHaustMRulandVet al.Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial.Rheumatology (Oxford)2010;49:(7)1336-1345
3.
BiondiMLMarasiniBBassaniCAgastoniAIncreased plasma endothelin levels in patients with Raynaud's phenomenon.N Engl J Med1991;324:(16)1139-1140
4.
YamaneKKashiwagiHSuzukiNet al.Elevated plasma levels of endothelin-1 in systemic sclerosis.Arthritis Rheum1991;34:(2)243-244
5.
AbrahamDJKriegTDistlerJDistlerOOverview of pathogenesis of systemic sclerosis.Rheumatology (Oxford)2009;48Suppl 3iii3-iii7
6.
RubinLJRouxSBosentan: a dual endothelin receptor antagonist.Expert Opin Investig Drugs2002;11:(7)991-1002
7.
DentonCPPopeJEPeterHHet al;TRacleer Use in PAH associated with Scleroderma and Connective Tissue Diseases (TRUST) Investigators. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.Ann Rheum Dis2008;67:(9)1222-1228
8.
KornJHMayesMMatucci CerinicMet al.Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.Arthritis Rheum2004;50:(12)3985-3993
9.
Matucci-CerinicMDentonCPFurstDEet al.Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.Ann Rheum Dis2011;70:(1)32-38
10.
SeiboldJRDentonCPFurstDEet al.Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.Arthritis Rheum2010;62:(7)2101-2108
11.
WalkerUATyndallACzirjákLet al.Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.Ann Rheum Dis2007;66:(6)754-763
12.
MeierFMFrommerKWDinserRet al;EUSTAR Co-authors.Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis2012;71:(8)1355-1360
13.
MaurerBGrafNMichelBAet al;EUSTAR co-authors.Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis2015;74:(6)1124-1131
14.
DobrotaRMaurerBGrafNet al.Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis – a EUSTAR Analysis [poster presentations].Ann Rheum Dis2015;74Suppl 2819
15.
Shi-WenXChenYDentonCPet al.Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts.Mol Biol Cell2004;15:(6)2707-2719
16.
LeaskATargeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma.Cell Signal2008;20:(8)1409-1414
17.
XuSWHowatSLRenzoniEAet al.Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK.J Biol Chem2004;279:(22)23098-23103
18.
Shi-WenXRenzoniEAKennedyLet al.Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts.Matrix Biol2007;26:(8)625-632
19.
IvyDMcMurtryIFYanagisawaMet al.Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction.Am J Physiol Lung Cell Mol Physiol2001;280:(5)L1040-L1048
20.
ParkSHSalehDGiaidAMichelRPIncreased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist.Am J Respir Crit Care Med1997;1562 Pt 1600-608
21.
RichardVSolansVFavreJet al.Role of endogenous endothelin in endothelial dysfunction in murine model of systemic sclerosis: tight skin mice 1.Fundam Clin Pharmacol2008;22:(6)649-655
22.
VancheeswaranRMagoulasTEfratGet al.Circulating endothelin-1 levels in systemic sclerosis subsets—a marker of fibrosis or vascular dysfunction?J Rheumatol1994;21:(10)1838-1844
23.
KahalehMBEndothelin, an endothelial-dependent vasoconstrictor in scleroderma.Enhanced production and profibrotic action. Arthritis Rheum1991;34:(8)978-983
24.
CambreyADHarrisonNKDawesKEet al.Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro.Am J Respir Cell Mol Biol1994;11:(4)439-445
25.
FuruyaYKuwanaMEffect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.J Rheumatol2011;38:(10)2186-2192
26.
GiordanoNPuccettiLPapakostasPet al.Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study.Int J Immunopathol Pharmacol2010;23:(4)1185-1194
27.
DistlerOCozzioASystemic sclerosis and localized scleroderma-current concepts and novel targets for therapy.Semin Immunopathol2016;38:(1)87-95
28.
JordanSChungJDistlerOPreclinical and translational research to discover potentially effective antifibrotic therapies in systemic sclerosis.Curr Opin Rheumatol2013;25:(6)679-685
29.
HocherBSchwarzAFaganKAet al.Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice.Am J Respir Cell Mol Biol2000;23:(1)19-26
30.
MendozaFAKeyes-ElsteinLLJimenezSASystemic sclerosis disease modification clinical trials design: quo vadis?Arthritis Care Res (Hoboken)2012;64:(7)945-954
31.
PopeJEKhannaDJohnsonSRClementsPDisease modification and other trials in systemic sclerosis have come a long way, but have to go further.Arthritis Care Res (Hoboken)201264:(7)955-959
32.
JohnsonSRKhannaDAllanoreYMatucci-CerinicMFurstDESystemic sclerosis trial design moving forward.Journal of Scleroderma and Related Disorders2016;1:(2)177-180
33.
FurstDEPopeJESeiboldJRet al.Progress and priorities in systemic sclerosis: the next 10 years – report from the World Scleroderma Foundation.Journal of Scleroderma and Related Disorders2016;1:(1)7-9
